In brief
Nigeria, facing the highest malaria death toll globally, has initiated the distribution of the R21/Matrix-M vaccine for children aged 5 to 15 months in an effort to combat the epidemic and promote public health.
Nigeria has commenced the distribution of the R21/Matrix-M malaria vaccine, marking a significant step in its fight against a disease that claims more lives in this nation than anywhere else in the world. The initiative began in the two states hardest hit by malaria, Bayelsa and Kebbi, with plans for a nationwide rollout by next year. The vaccine, which is particularly targeting children aged 5 to 15 months, has been approved by the World Health Organization (WHO) and boasts a 75% efficacy rate. Health professionals emphasize that while the vaccine is a substantial advancement, it is vital for it to be used in conjunction with other preventive measures, including mosquito nets and insect repellents.At the vaccine's launch event in Bayelsa, a mother named Happiness Idia-Wilson brought her 11-month-old son to receive the first dosage. "I do this for the safety of my child," she affirmed and encouraged other mothers to follow suit.Prof Seiyefa Brisibe, Bayelsa’s health commissioner, assured that health campaigns would be carried out in local languages to promote awareness and uptake of the vaccine. With Nigeria accounting for nearly a third of the world's malaria deaths—27% of cases and a staggering 31% of global fatalities—children under five years and pregnant women remain the most at risk.According to the WHO, Africa overall comprises 95% of malaria deaths, translating to approximately 580,000 fatalities annually. Dr. Walter Mulombo, the WHO representative in Nigeria, expressed confidence that the introduction of this vaccine, along with existing preventive strategies, could significantly lessen the malaria burden in Nigeria and help achieve a malaria-free continent. The toll of malaria extends beyond health, with Nigeria reportedly losing about $1.1bn (£870m) annually due to decreased productivity and associated health expenditures. The vaccine, developed by the Jenner Institute at Oxford University, requires three doses spaced four weeks apart and a booster shot one year later. Recent campaigns in Ivory Coast and the Democratic Republic of Congo echo Nigeria’s efforts, as other African nations—Ghana, Kenya, and Malawi—have previously trialed a different malaria vaccine, RTS,S. This monumental step aims to galvanize public health and transform the lives of countless families affected by malaria across Nigeria.
